de Hoyos-Alonso M C, Tapias-Merino E, Meseguer Barros C M, Sánchez-Martínez M, Otero A
Servicio Madrileño de Salud, Centro de Salud Pedro Laín Entralgo, Alcorcón, Madrid, España.
Servicio Madrileño de Salud, Centro de Salud Comillas, Área Centro, Madrid, España.
Neurologia. 2015 Sep;30(7):416-24. doi: 10.1016/j.nrl.2014.02.007. Epub 2014 Apr 4.
Analysing drug consumption in large population groups lets us observe consumption trends and compare them between different settings.
to analyse the time trends for consumption and costs of specific drugs used to treat dementia in the region of Madrid (Spain) and compare trends by sex and age cohort.
Descriptive study of cholinesterase inhibitors (N06DA) and memantine (N06DX01) dispensed in Madrid between 2002 and 2012 and covered by the Spain's national health system. Consumption was calculated by analysing changes in DDD (defined daily doses) to find total and yearly increases. The cost was estimated based on DDD price. To compare consumption rates by age and sex, we calculated DDD per 100 inhabitants/day.
Between 2002 and 2012, consumption of drugs used to treat dementia increased sixfold. During this period, cholinesterase inhibitors accounted for 76.70% of the drugs consumed and memantine, 23.30%. The estimated cost rose by a by a factor of 5.7 over 11 years (or by a factor of 4 taking into account the use of generic drugs). In 2012, 2.42% of the patients aged 65 or over consumed cholinesterase inhibitors (women 2.82%, men 1.83%) and 0.90% consumed memantine (women 1.10%, men 0.61%). Consumption increased in age cohorts up to 86 to 90 (5.84% for cholinesterase inhibitors and 2.33% for memantine) and declined thereafter.
Consumption of cholinesterase inhibitors and memantine gradually increased, but consumption in 2012 did not reach levels equivalent to dementia prevalence figures. Pharmaceutical expenditure restraint measures may temporarily slow the cost increase temporarily but if the same trend of consumption persists, costs will rise.
分析大量人群的药物消费情况能让我们观察消费趋势，并在不同环境下进行比较。
分析西班牙马德里地区用于治疗痴呆症的特定药物的消费和成本的时间趋势，并按性别和年龄组比较趋势。
对2002年至2012年期间在马德里分发并由西班牙国家卫生系统承保的胆碱酯酶抑制剂（N06DA）和美金刚（N06DX01）进行描述性研究。通过分析限定日剂量（DDD）的变化来计算消费量，以找出总量和年度增长情况。成本根据DDD价格估算。为按年龄和性别比较消费率，我们计算了每100居民/天的DDD。
2002年至2012年期间，用于治疗痴呆症的药物消费增长了六倍。在此期间，胆碱酯酶抑制剂占消费药物的76.70%，美金刚占23.30%。估计成本在11年中增长了5.7倍（考虑到使用仿制药则增长了4倍）。2012年，65岁及以上患者中2.42%消费胆碱酯酶抑制剂（女性为2.82%，男性为1.83%），0.90%消费美金刚（女性为1.10%，男性为0.61%）。年龄组中直至86至90岁消费均有所增加（胆碱酯酶抑制剂为5.84%，美金刚为2.33%），此后下降。
胆碱酯酶抑制剂和美金刚的消费逐渐增加，但2012年的消费量未达到与痴呆症患病率相当的水平。药品支出限制措施可能会暂时减缓成本增长，但如果消费趋势持续不变，成本仍将上升。
